M&A Deal Summary

Deerfield Management Acquires Endologix

On July 5, 2020, venture capital firm Deerfield Management acquired medical products company Endologix

Acquisition Highlights
  • This is Deerfield Management’s 1st transaction in the Medical Products sector.
  • This is Deerfield Management’s 2nd transaction in the United States.
  • This is Deerfield Management’s 2nd transaction in California.

M&A Deal Summary
Date 2020-07-05
Target Endologix
Sector Medical Products
Buyer(s) Deerfield Management
Deal Type Going Private

Target

Endologix

Irvine, California, United States
Endologix is a medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix was founded in 1992 and is based in Irvine, California.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Deerfield Management

Investor Investor Investor Investor Investor

Category Venture Capital Firm
Founded 1994
PE ASSETS 8.0B USD
Size Mega
Type Sector Focused
DESCRIPTION

Deerfield Management is a hedge fund sponsor focused on public and private company investments in the healthcare sector. Deerfield was established in 1994 and is headquartered in New York City.

DEAL STATS #
Overall 2 of 3
Sector (Medical Products) 1 of 1
Type (Going Private) 1 of 1
State (California) 2 of 2
Country (United States) 2 of 3
Year (2020) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-06-21 Ablexis

San Francisco, California, United States

Ablexis is a developer of AlivaMab Mouse technology, a unique, patented next- generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis was founded in 2009 and is based in San Francisco, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-03-01 Parabilis Medicines

Cambridge, Massachusetts, United States

Parabilis Medicines is a biopharmaceutical company with a mission to drastically reduce the burden of disease on patients and their families by inventing new types of drugs that squelch abnormal physiological processes in ways previously imagined but considered unattainable. The company is pioneering the discovery, development and commercialization of Helicon™ peptides, a new drug modality that uniquely combines the cell-permeability and oral dosing optionality of traditional small molecule drugs with the high specificity, broad target accessibility and rapid discovery arc of monoclonal antibody drugs. Parabilis Medicines was founded in 2016 and is based in Cambridge, Massachusetts.

Buy -
Mergr

Product

Company

Legal